bullish

DualityBio (9606 HK) - Emerging as a Global Leader in ADC Innovation...

296 Views10 Jun 2025 01:27
Broker
Differentiated ADC product pipeline. DualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation.
What is covered in the Full Insight:
  • Investment thesis
  • Differentiated ADC product pipeline
  • Eye on global markets with a replicable partnership model
  • Initiate at BUY with TP of HK$270.34
  • DB-1311/BNT324, a B7-H3 ADC candidate with global market potential
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 72-minute read)
Related Insights
More »
    Loading
Trending Collections
More »
    Loading
Trending Insights
More »
    Loading
Top Unpaywalled Insights
More »
    Loading
Discussions
(Paid Plans Only)
chart-bar
Logo
CMB International
External broker reports(aggregated public sources)
CMB International
China & Hong KongEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x